Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RANDAL S WEBER and DAVID ROSENTHAL.
RANDAL S WEBER
Connection Strength
4.977
DAVID ROSENTHAL
  1. Postoperative treatment intensification for improving outcome in the high-risk patient: an evolutionary process. Head Neck. 2005 Oct; 27(10):841-2.
    View in: PubMed
    Score: 0.266
  2. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
    View in: PubMed
    Score: 0.168
  3. Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope. 2020 01; 130(1):146-153.
    View in: PubMed
    Score: 0.168
  4. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8.
    View in: PubMed
    Score: 0.156
  5. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck?Cancer. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1002-1011.
    View in: PubMed
    Score: 0.150
  6. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016 12; 38(12):1739-1751.
    View in: PubMed
    Score: 0.141
  7. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15; 121(10):1608-19.
    View in: PubMed
    Score: 0.126
  8. Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. Ann Surg Oncol. 2015 Aug; 22(8):2755-60.
    View in: PubMed
    Score: 0.126
  9. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7.
    View in: PubMed
    Score: 0.107
  10. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46.
    View in: PubMed
    Score: 0.103
  11. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck. 2012 Sep; 34(9):1263-8.
    View in: PubMed
    Score: 0.101
  12. Compliance with quality assurance measures in patients treated for early oral tongue cancer. Cancer. 2010 Jul 15; 116(14):3408-16.
    View in: PubMed
    Score: 0.093
  13. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009 Dec 15; 115(24):5723-33.
    View in: PubMed
    Score: 0.089
  14. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 01; 27(28):4727-32.
    View in: PubMed
    Score: 0.087
  15. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol. 2008 Nov 01; 26(31):5119-25.
    View in: PubMed
    Score: 0.081
  16. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007 Oct; 29(10):923-31.
    View in: PubMed
    Score: 0.076
  17. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007 Jun; 133(6):546-50.
    View in: PubMed
    Score: 0.075
  18. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer. 2007 Apr 01; 109(7):1331-43.
    View in: PubMed
    Score: 0.074
  19. Radiation-induced xerostomia. Head Neck. 2007 Jan; 29(1):58-63.
    View in: PubMed
    Score: 0.072
  20. Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck. 2006 Nov; 28(11):967-73.
    View in: PubMed
    Score: 0.072
  21. Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument. Am J Clin Oncol. 2006 Apr; 29(2):158-62.
    View in: PubMed
    Score: 0.069
  22. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol. 2005 Aug; 28(4):385-92.
    View in: PubMed
    Score: 0.066
  23. Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005 Mar; 7(2):131-6.
    View in: PubMed
    Score: 0.064
  24. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol. 2004 Dec; 31(6 Suppl 18):25-8.
    View in: PubMed
    Score: 0.063
  25. Controversies in the management of advanced laryngeal squamous cell carcinoma. Cancer. 2004 Jul 15; 101(2):211-9.
    View in: PubMed
    Score: 0.061
  26. Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx. AJNR Am J Neuroradiol. 2004 Jun-Jul; 25(6):1092-8.
    View in: PubMed
    Score: 0.061
  27. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):72-7.
    View in: PubMed
    Score: 0.060
  28. Impact of Cancer Care Regionalization on Patient Volume. Ann Surg Oncol. 2023 Apr; 30(4):2331-2338.
    View in: PubMed
    Score: 0.055
  29. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):533-543.
    View in: PubMed
    Score: 0.055
  30. Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy. Head Neck. 2002 Dec; 24(12):1068-71.
    View in: PubMed
    Score: 0.055
  31. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. Laryngoscope. 2002 Oct; 112(10):1883-7.
    View in: PubMed
    Score: 0.054
  32. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs. 2002 Aug; 20(3):343-9.
    View in: PubMed
    Score: 0.053
  33. Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncol. 2022 07; 130:105906.
    View in: PubMed
    Score: 0.053
  34. Parotidectomy in the treatment of aggressive cutaneous malignancies. Arch Otolaryngol Head Neck Surg. 2002 May; 128(5):521-6.
    View in: PubMed
    Score: 0.052
  35. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.052
  36. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002 Feb; 24(2):115-26.
    View in: PubMed
    Score: 0.052
  37. Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001 Sep-Oct; 22(5):329-35.
    View in: PubMed
    Score: 0.050
  38. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
    View in: PubMed
    Score: 0.050
  39. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.049
  40. The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. J Geriatr Oncol. 2021 07; 12(6):937-944.
    View in: PubMed
    Score: 0.049
  41. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001 Mar 01; 19(5):1363-73.
    View in: PubMed
    Score: 0.048
  42. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.048
  43. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.048
  44. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.048
  45. Pilot study of organ preservation multimodality therapy for locally advanced resectable oropharyngeal carcinoma. Am J Clin Oncol. 2000 Oct; 23(5):509-15.
    View in: PubMed
    Score: 0.047
  46. Allograft dermal implant (AlloDerm) in a previously irradiated field. Laryngoscope. 2000 Jun; 110(6):934-7.
    View in: PubMed
    Score: 0.046
  47. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
    View in: PubMed
    Score: 0.046
  48. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.045
  49. Effects of external beam radiation on the allograft dermal implant. Otolaryngol Head Neck Surg. 2000 Feb; 122(2):189-94.
    View in: PubMed
    Score: 0.045
  50. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope. 1999 Jun; 109(6):970-5.
    View in: PubMed
    Score: 0.043
  51. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):311-5.
    View in: PubMed
    Score: 0.043
  52. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):97-101.
    View in: PubMed
    Score: 0.042
  53. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer. 2019 06 15; 125(12):2027-2038.
    View in: PubMed
    Score: 0.042
  54. In Regard to Bossi et?al. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):669-670.
    View in: PubMed
    Score: 0.041
  55. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998 Aug; 124(8):871-5.
    View in: PubMed
    Score: 0.040
  56. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 09; 40(9):2060-2069.
    View in: PubMed
    Score: 0.040
  57. Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
    View in: PubMed
    Score: 0.039
  58. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
    View in: PubMed
    Score: 0.038
  59. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Dec 20; 35(36):4057-4065.
    View in: PubMed
    Score: 0.038
  60. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
    View in: PubMed
    Score: 0.037
  61. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):687-699.
    View in: PubMed
    Score: 0.035
  62. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):667-677.
    View in: PubMed
    Score: 0.035
  63. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1117-31.
    View in: PubMed
    Score: 0.034
  64. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head Neck. 2016 04; 38 Suppl 1:E2091-9.
    View in: PubMed
    Score: 0.034
  65. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral Oncol. 2015 Feb; 51(2):195-201.
    View in: PubMed
    Score: 0.031
  66. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec 01; 32(34):3858-66.
    View in: PubMed
    Score: 0.031
  67. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27):2940-50.
    View in: PubMed
    Score: 0.031
  68. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):846-53.
    View in: PubMed
    Score: 0.030
  69. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.028
  70. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
    View in: PubMed
    Score: 0.026
  71. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011 Jan; 137(1):78-81.
    View in: PubMed
    Score: 0.024
  72. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 01; 363(1):24-35.
    View in: PubMed
    Score: 0.023
  73. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10.
    View in: PubMed
    Score: 0.023
  74. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74.
    View in: PubMed
    Score: 0.022
  75. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009 Aug; 31(8):1031-8.
    View in: PubMed
    Score: 0.022
  76. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15.
    View in: PubMed
    Score: 0.021
  77. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.020
  78. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008 May 01; 112(9):2088-100.
    View in: PubMed
    Score: 0.020
  79. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15; 110(12):2726-31.
    View in: PubMed
    Score: 0.019
  80. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52.
    View in: PubMed
    Score: 0.019
  81. Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):678-83.
    View in: PubMed
    Score: 0.017
  82. ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol. 2005 Jul; 41(6):580-8.
    View in: PubMed
    Score: 0.016
  83. Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. Mod Pathol. 2005 Mar; 18(3):315-9.
    View in: PubMed
    Score: 0.016
  84. Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctive features of biological significance. Am J Surg Pathol. 2004 Oct; 28(10):1299-310.
    View in: PubMed
    Score: 0.015
  85. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.015
  86. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res. 2004 Jun 01; 10(11):3825-30.
    View in: PubMed
    Score: 0.015
  87. Reinterpretation of cross-sectional images in patients with head and neck cancer in the setting of a multidisciplinary cancer center. AJNR Am J Neuroradiol. 2002 Nov-Dec; 23(10):1622-6.
    View in: PubMed
    Score: 0.014
  88. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol. 2002 Oct 01; 20(19):3964-71.
    View in: PubMed
    Score: 0.013
  89. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002 Mar; 8(3):885-92.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.